Association of polymorphisms in CYP2C8 and CYP2C9 with susceptibility to type 2 diabetes mellitus in a Chinese population

被引:0
作者
Wang, Wensu [1 ]
Jin, Li [2 ]
Shen, Jianguo [2 ]
Zhang, Yi [3 ]
Zhang, Rong [3 ]
机构
[1] Guizhou Univ TCM, Affiliated Hosp 2, Dept Geriatr, 83 Feishan Rd, Guiyang 550003, Guizhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol & Metab, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Clin Ctr Diabet, Shanghai Diabet Inst, Affiliated Peoples Hosp 6,Shanghai Key Lab Diabet, Shanghai 200233, Peoples R China
来源
GENE REPORTS | 2024年 / 37卷
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Arachidonic acid; Genetic polymorphisms; Type 2 diabetes mellitus; INSULIN SENSITIVITY; RISK-FACTORS; CYTOCHROME-P450; EPIDEMIOLOGY; GLUCOSE; INFLAMMATION; EXPRESSION; DISEASE; ACID;
D O I
10.1016/j.genrep.2024.102053
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aims: CYP2C8 and CYP2C9 are cytochrome P450 epoxygenases responsible for metabolizing arachidonic acid into epoxyeicosatrienoic acids (EETs). These EETs play a crucial role as lipid mediators with numerous beneficial effects in type 2 diabetes mellitus (T2DM). In this study, we aimed to investigate the association of CYP2C8 and CYP2C9 genetic variants with T2DM in a Chinese population. Methods: We conducted genotyping for 9 tag single nucleotide polymorphisms (SNPs) in CYP2C8 and 10 tag SNPs in CYP2C9 based on HapMap Chinese and Japanese data. Subsequently, we genotyped these SNPs in a Chinese cohort comprising 3410 individuals with T2DM and 3401 healthy controls. Statistical analyses were performed to assess the association between these SNPs and T2DM. Results: In our study population, we observed that rs1819173, located within the CYP2C9 gene region, was significantly associated with T2DM. Notably, the presence of the A allele was found to be protective against T2DM, as indicated by an odds ratio of 0.840 (95 % confidence interval: 0.780-0.904, P = 3.04 x 10-6). Furthermore, specific haplotypes (GT and AT) involving rs2071426 and rs6583967 in CYP2C8 exhibited associations with T2DM (P = 0.049 and 0.038, respectively). Subsequently, we conducted an analysis of the association between rs1819173 and non-alcoholic fatty liver disease (NAFLD), revealing a significant correlation (OR = 0.764, 95 % CI: 0.629-0.928, P = 0.007). Conclusion: Our research identified a genetic variants rs1819173 within CYP2C8 are significantly associated with T2DM susceptibility in the Chinese population.
引用
收藏
页数:7
相关论文
共 48 条
  • [1] Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    Backman, Janne T.
    Filppula, Anne M.
    Niemi, Mikko
    Neuvonen, Pertti J.
    [J]. PHARMACOLOGICAL REVIEWS, 2016, 68 (01) : 168 - 241
  • [2] Environmental risk factors of type 2 diabetes-an exposome approach
    Beulens, Joline W. J.
    Pinho, Maria G. M.
    Abreu, Taymara C.
    den Braver, Nicole R.
    Lam, Thao M.
    Huss, Anke
    Vlaanderen, Jelle
    Sonnenschein, Tabea
    Siddiqui, Noreen Z.
    Yuan, Zhendong
    Kerckhoffs, Jules
    Zhernakova, Alexandra
    Brandao Gois, Milla F.
    Vermeulen, Roel C. H.
    [J]. DIABETOLOGIA, 2022, 65 (02) : 263 - 274
  • [3] Orally Active Epoxyeicosatrienoic Acid Analogs
    Campbell, William B.
    Imig, John D.
    Schmitz, James M.
    Falck, John R.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 70 (04) : 211 - 224
  • [4] Diabetes in Asia Epidemiology, Risk Factors, and Pathophysiology
    Chan, Juliana C. N.
    Malik, Vasanti
    Jia, Weiping
    Kadowaki, Takashi
    Yajnik, Chittaranjan S.
    Yoon, Kun-Ho
    Hu, Frank B.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (20): : 2129 - 2140
  • [5] The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms
    Cooper-DeHoff, Rhonda M.
    Niemi, Mikko
    Ramsey, Laura B.
    Luzum, Jasmine A.
    Tarkiainen, E. Katriina
    Straka, Robert J.
    Gong, Li
    Tuteja, Sony
    Wilke, Russell A.
    Wadelius, Mia
    Larson, Eric A.
    Roden, Dan M.
    Klein, Teri E.
    Yee, Sook Wah
    Krauss, Ronald M.
    Turner, Richard M.
    Palaniappan, Latha
    Gaedigk, Andrea
    Giacomini, Kathleen M.
    Caudle, Kelly E.
    Voora, Deepak
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (05) : 1007 - 1021
  • [6] Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review
    Das, Undurti N.
    [J]. JOURNAL OF ADVANCED RESEARCH, 2018, 11 : 43 - 55
  • [7] Development of an In Vitro System with Human Liver Microsomes for Phenotyping of CYP2C9 Genetic Polymorphisms with a Mechanism-Based Inactivator
    Flora, Darcy R.
    Tracy, Timothy S.
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 836 - 842
  • [8] Modulation of CYP450 Activities in Patients With Type 2 Diabetes
    Gravel, Sophie
    Chiasson, Jean-Louis
    Turgeon, Jacques
    Grangeon, Alexia
    Michaud, Veronique
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (06) : 1280 - 1289
  • [9] Validation of the insulin sensitivity index (ISI0,120):: comparison with other measures
    Gutt, M
    Davis, CL
    Spitzer, SB
    Llabre, MM
    Kumar, M
    Czarnecki, EM
    Schneiderman, N
    Skyler, JS
    Marks, JB
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 47 (03) : 177 - 184
  • [10] Soluble epoxide hydrolase: A potential target for metabolic diseases
    He, Jinlong
    Wang, Chunjiong
    Zhu, Yi
    Ai, Ding
    [J]. JOURNAL OF DIABETES, 2016, 8 (03) : 305 - 313